Ann: Appendix 4C - quarterly, page-5

50% staff reduction! ... very likely due to Axovant debacle.

“Management has taken steps to streamline operations and ensure our primary ddRNAi product candidate, BB-301, will progress to receive meaningful data from clinical trials. Management recently conducted a reduction in the workforce to align key staff members with the company’s strategic goals.”

Sounds like OPMD will determine the future of the company and this does not look good.